US 11278632
Engineered nucleases useful for treatment of hemophilia A
granted A61KA61K38/00A61K38/465
Quick answer
US patent 11278632 (Engineered nucleases useful for treatment of hemophilia A) held by Precision BioSciences, Inc. expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Precision BioSciences, Inc.
- Grant date
- Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K38/465, A61K48/005, A61K48/0066